Chronic Myeloid Leukemia Market Expected to Experience Major Growth by 2032, According to DelveInsight | Terns Pharma, Ascentage Pharma, Novartis, M.D. Anderson Cancer Center, Kartos Therapeutics

Posted on
by

Chronic Myeloid Leukemia Market Expected to Experience Major Growth by 2032, According to DelveInsight | Terns Pharma, Ascentage Pharma, Novartis, M.D. Anderson Cancer Center, Kartos Therapeutics
The Key Chronic Myeloid Leukemia Companies in the market include – Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, Novartis, M.D. Anderson Cancer Center, Kartos Therapeutics, Groupe Francophone des Myelodysplasies, University of Jena, Takeda, Il-Yang Pharm. Co., Ltd., Shenzhen TargetRx, Inc., Bristol-Myers Squibb, Astex Pharmaceuticals, Inc., and others.

 

DelveInsight’s “Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Myeloid Leukemia, historical and forecasted epidemiology as well as the Chronic Myeloid Leukemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Chronic Myeloid Leukemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Myeloid Leukemia Market Forecast

 

Some of the key facts of the Chronic Myeloid Leukemia Market Report:

  • The Chronic Myeloid Leukemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In February 2025, Cipla has obtained final approval from the US FDA for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML). The product is anticipated to be launched in the US during FY2025-26.

  • In November 2024, Marks Shorla Oncology has announced FDA approval for imatinib (Imkeldi), the first oral liquid tyrosine kinase inhibitor (TKI) authorized for treating multiple cancers, including gastrointestinal stromal tumors (GIST), myelodysplastic syndromes (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

  • In November 2024, The U.S. Food and Drug Administration (FDA) has approved a reformulated version of nilotinib (Danziten) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase. The approval also covers adult patients in the chronic or acute phase of CML who have shown resistance or intolerance to previous treatments, including imatinib.

  • In October 2024, Novartis has obtained accelerated approval from the U.S. Food and Drug Administration (FDA) for Scemblix (asciminib) for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).

  • In January 2024, Terns Pharmaceuticals expected significant proof-of-concept results for TERN-701 (for Chronic Myeloid Leukemia) by the latter half of 2024.

  • In January 2024, Novartis reported favorable outcomes from the primary analysis of ASC4FIRST, a critical Phase III trial that compared SCEMBLIX against the preferred tyrosine kinase inhibitor (TKI) treatment chosen by investigators. This study focused on newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

  • According to projections by the American Cancer Society, around 9,280 individuals in the United States are expected to be diagnosed with CML in 2024, including 5,330 cases in men and 3,950 cases in women.

  • According to the NICE UK, CML has an annual incidence of 4.2 cases per 100,000 individuals. Additionally, CML accounts for only 5% of childhood leukemia cases. Moreover, it is noted that 85-90% of patients are diagnosed during the chronic phase of the disease.

  • In 2022, based on SEER data, it is projected that there will be approximately 8,860 new cases of CML in the United States.

  • Key Chronic Myeloid Leukemia Companies: Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, Novartis, M.D. Anderson Cancer Center, Kartos Therapeutics, Groupe Francophone des Myelodysplasies, University of Jena, Takeda, Il-Yang Pharm. Co., Ltd., Shenzhen TargetRx, Inc., Bristol-Myers Squibb, Astex Pharmaceuticals, Inc., and others

  • Key Chronic Myeloid Leukemia Therapies: ELVN-001, TERN-701, HQP1351, ABL001, Asciminib, KRT-232, Venetoclax, Imatinib, Ponatinib, Radotinib, TGRX-678, Dasatinib, Azacitidine, and others

  • The Chronic Myeloid Leukemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Myeloid Leukemia pipeline products will significantly revolutionize the Chronic Myeloid Leukemia market dynamics.

 

Chronic Myeloid Leukemia Overview

Chronic Myeloid Leukemia (CML) is a type of cancer that begins in the blood-forming cells of the bone marrow. It is characterized by the uncontrolled growth of immature myeloid cells, which are a type of white blood cells. In CML, there is a genetic abnormality called the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22. This translocation leads to the formation of a fusion gene called BCR-ABL1, which produces a protein that promotes the excessive growth of myeloid cells.

 

Get a Free sample for the Chronic Myeloid Leukemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market

 

Chronic Myeloid Leukemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Chronic Myeloid Leukemia Epidemiology Segmentation:

The Chronic Myeloid Leukemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chronic Myeloid Leukemia

  • Prevalent Cases of Chronic Myeloid Leukemia by severity

  • Gender-specific Prevalence of Chronic Myeloid Leukemia

  • Diagnosed Cases of Episodic and Chronic Chronic Myeloid Leukemia

 

Download the report to understand which factors are driving Chronic Myeloid Leukemia epidemiology trends @ Chronic Myeloid Leukemia Epidemiology Forecast

 

Chronic Myeloid Leukemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Myeloid Leukemia market or expected to get launched during the study period. The analysis covers Chronic Myeloid Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Myeloid Leukemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Chronic Myeloid Leukemia Therapies and Key Companies

  • ELVN-001: Enliven Therapeutics

  • TERN-701: Terns Pharmaceuticals

  • HQP1351: Ascentage Pharma

  • ABL001: Novartis

  • Asciminib: M.D. Anderson Cancer Center

  • KRT-232: Kartos Therapeutics

  • Venetoclax: Groupe Francophone des Myelodysplasies

  • Imatinib: University of Jena

  • Ponatinib: Takeda

  • Radotinib: Il-Yang Pharm. Co., Ltd.

  • TGRX-678: Shenzhen TargetRx, Inc.

  • Dasatinib: Bristol-Myers Squibb

  • Azacitidine: Astex Pharmaceuticals, Inc.

 

Discover more about therapies set to grab major Chronic Myeloid Leukemia market share @ Chronic Myeloid Leukemia Treatment Landscape

 

Chronic Myeloid Leukemia Market Strengths

  • Premium-price agents with superior efficacy such as immunotherapies and kinase inhibitors are expected to dominate the Chronic Myeloid Leukemia market.

  • Novel treatments like SCEMBLIX (asciminib) demonstrate specific targeting of the ABL myristoyl pocket, leading to improved safety and tolerability compared to current standard care.

 

Chronic Myeloid Leukemia Market Opportunities

  • Currently limited treatment options available for relapsed and refractory cases in Chronic Myeloid Leukemia.

  • Participation in and support for clinical trials provide opportunities to evaluate novel therapies, contributing to advancements in Chronic Myeloid Leukemia management.

 

Scope of the Chronic Myeloid Leukemia Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Chronic Myeloid Leukemia Companies: ELVN-001, TERN-701, HQP1351, ABL001, Asciminib, KRT-232, Venetoclax, Imatinib, Ponatinib, Radotinib, TGRX-678, Dasatinib, Azacitidine, and others

  • Key Chronic Myeloid Leukemia Therapies: ELVN-001, TERN-701, HQP1351, ABL001, Asciminib, KRT-232, Venetoclax, Imatinib, Ponatinib, Radotinib, TGRX-678, Dasatinib, Azacitidine, and others

  • Chronic Myeloid Leukemia Therapeutic Assessment: Chronic Myeloid Leukemia current marketed and Chronic Myeloid Leukemia emerging therapies

  • Chronic Myeloid Leukemia Market Dynamics: Chronic Myeloid Leukemia market drivers and Chronic Myeloid Leukemia market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Chronic Myeloid Leukemia Unmet Needs, KOL’s views, Analyst’s views, Chronic Myeloid Leukemia Market Access and Reimbursement

 

To know more about Chronic Myeloid Leukemia companies working in the treatment market, visit @ Chronic Myeloid Leukemia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Chronic Myeloid Leukemia Market Report Introduction

2. Executive Summary for Chronic Myeloid Leukemia

3. SWOT analysis of Chronic Myeloid Leukemia

4. Chronic Myeloid Leukemia Patient Share (%) Overview at a Glance

5. Chronic Myeloid Leukemia Market Overview at a Glance

6. Chronic Myeloid Leukemia Disease Background and Overview

7. Chronic Myeloid Leukemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Myeloid Leukemia

9. Chronic Myeloid Leukemia Current Treatment and Medical Practices

10. Chronic Myeloid Leukemia Unmet Needs

11. Chronic Myeloid Leukemia Emerging Therapies

12. Chronic Myeloid Leukemia Market Outlook

13. Country-Wise Chronic Myeloid Leukemia Market Analysis (2019–2032)

14. Chronic Myeloid Leukemia Market Access and Reimbursement of Therapies

15. Chronic Myeloid Leukemia Market Drivers

16. Chronic Myeloid Leukemia Market Barriers

17. Chronic Myeloid Leukemia Appendix

18. Chronic Myeloid Leukemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/